tbuckley/cabot-search huggingface dataset:
Feasibility of Allogeneic Hematopoietic Stem Cell Transplant for High Risk FLT3-ITD Mutant Patients with Acute Myeloid Leukemia in CR1- a Real Word Analysis
Authors: Ankit J. Kansagra, Hassan B Alkhateeb, Mehrdad Hefazi, Fevzi Yalniz, William J Hogan, Mark R Litzow, Mrinal M Patnaik
Journal: Blood (2016)
Pharmacokinetics, Pharmacodynamics and Anti-Tumor Efficacy of PR-171, a Novel Inhibitor of the 20S Proteasome.
Authors: Christopher J. Kirk, Mark K. Bennett, Tonia J. Buchholz, Susan D. Demo, Mark N. Ho, Jing Jiang, Guy J. Laidig, Evan R. Lewis, Kevin D. Shenk, Mark S. Smyth, Congcong M. Sun, Marcy K. Vallone, Tina M. Woo, Christopher J. Molineaux
Journal: Blood (2005)
Extended Follow-up of the Multi-Center Multi-National Prospective Cohort Study That Derived the “Men Continue and HERDOO2” Clinical Decision Rule Which Identifies Low Risk Patients Who May Be Able to Discontinue Oral Anticoagulants (Oac) 5-7 Months After Treatment for Unprovoked Venous Thromboembolism (VTE).
Authors: Marc Rodger, Michael J. Kovacs, Susan Kahn, Phil Wells, David Anderson, Le Gal Gregoire, Susan Solymoss, Isabelle Chagnon, Mark A. Crowther, Arnaud Perrier, Richard H. White, Marisol Betancourt, Marc Carrier
Journal: Blood (2009)
Adoptive Immune Cell Therapy Using Third Party T-Cell Donors In the Treatment of EBV Related Diseases In Immunodeficient Recipients
Authors: Susan Prockop, Ekaterina Doubrovina, Farid Boulad, Nancy A Kernan, Rachel Kobos, Andromachi Scaradavou, Trudy N Small, Ramzi Khalaf, Juliet Barker, Guenther Koehne, Esperanza Papadopoulos, James W. Young, Richard J. O'Reilly
Journal: Blood (2010)
Prognostic Understanding, Quality of Life, and Mood in Patients Undergoing Hematopoietic Stem Cell Transplantation
Authors: Areej El-Jawahri, Lara Traeger, Kailyn Kuzmuk, Justin Eusebio, Harry Vandusen, Jennifer Shin, Emily Gallagher, Joseph Greer, William Pirl, Vicki Jackson, Karen K. Ballen, Thomas R. Spitzer, Timothy A. Graubert, Steven L. McAfee, Bimalangshu R. Dey, Yi-Bin Chen, Jennifer S. Temel
Journal: Blood (2014)
A Phase I/II Study of Bortezomib (VELCADE) in Combination with Pralatrexate in Relapsed/Refractory Multiple Myeloma
Authors: Tamara J. Dunn, Shira N. Dinner, Caroline Berube, Jason Gotlib, Steven E. Coutre, Bruno C. Medeiros, Michaela Liedtke
Journal: Blood (2012)
Prognostic Factors Of Response and Survival To Azacitidine (AZA) +/- EPO In RBC Transfusion Dependent (TD) IPSS Low and Int-1 (LR) MDS Resistant To EPO, With Particular Emphasis Of Genetic Lesions: A Study By The GFM
Authors: Sylvain Thepot, Raouf Ben Abdelali, Sylvie Chevret, Aline Renneville, Odile Beyne Rauzy, Thomas Prebet, Sophie Park, Aspasia Stamatoullas, Agnès Guerci-Bresler, Stéphane Cheze, Gerard Tertian, Bachra Choufi, Laurence Legros, Jean-Noel Bastie, Jacques Delaunay, Eric Wattel, Francois Dreyfus, Norbert Vey, Claude Preudhomme, Pierre Fenaux, Claude Gardin
Journal: Blood (2013)
Endothelin-1 Is Associated with Albuminuria and Measures of Vascular Endothelial Dysfunction in Sickle Cell Anemia
Authors: Vimal K. Derebail, Susan K Jones, Jessica Shen, Melissa Caughey, Alan L. Hinderliter, David M. Pollock, David R. Archer, Kenneth I. Ataga
Journal: Blood (2015)
Psychiatrist plans to leave NHS if his mother is refused permission to stay in UK
Authors: Clare Dyer
Journal: BMJ (2019)

An experienced consultant child psychiatrist plans to leave the NHS and move to Australia unless the Home Office grants his widowed mother permission to stay in the UK by Christmas.

Nishchint Warikoo, lead child psychiatrist for child and adolescent mental health services in Hampshire, told The BMJ that he felt “hopeless, almost angry, and let down” by the system. “Every day for the last two years my mother anxiously waits to see if there is a letter saying she must leave within four weeks.”

He said he had been battling with the Home Office for years for his mother, Phoola, 71, who was born in India, to be allowed to continue living with him and …
Genomic Mechanisms of 17p / TP53 Loss in Primary “ultra High-risk” and Refractory Chronic Lymphocytic Leukemia: Results from the CLL2O Trial
Authors: Veronica Teleanu, Jennifer Edelmann, Claudia Haferlach, Stefan Ibach, Eugen Tausch, Johannes Bloehdorn, Veronique Leblond, Florence Cymbalista, Alain Delmer, Michael Hallek, Hartmut Doehner, Stephan Stilgenbauer
Journal: Blood (2014)
Intron Retention Coupled with Nonsense-Mediated Decay Determines Protein Expression and Nuclear Morphology in Granulopoiesis
Authors: John Rasko, Justin Wong, William Ritchie, Ebner Olivia, Selbach Matthias, Jason WH Wong, Yizhou Huang, Dadi Gao, Maria Gonzalez, Kinsha Baidya, Annora Theong, Teh-Liane Khoo, Charles G Bailey, Jeff Holst
Journal: Blood (2012)
High-Throughput Mutational Profiling In AML: Mutational Analysis of the ECOG E1900 Trial
Authors: Jay P. Patel, Omar Abdel-Wahab, Mithat Gonen, Maria E. Figueroa, Hugo F. Fernandez, Zhuoxin Sun, Janis Racevskis, Pieter Van lierberghe, Igor Dolgalev, Janice Cheng, Agnes Viale, Nicholas Socci, Adriana Heguy, Rhett Ketterling, Robert E. Gallagher, Mark R. Litzow, Jacob M. Rowe, Adolfo Ferrando, Elisabeth Paietta, Martin S. Tallman, Ari M. Melnick, Ross Levine
Journal: Blood (2010)
Long-Term Follow Up Of a Randomized Phase II Study Of The JAK2-Selective Inhibitor Fedratinib (SAR302503) In Patients With Myelofibrosis (MF)
Authors: Animesh Pardanani, Ayalew Tefferi, Catriona HM Jamieson, Nashat Y Gabrail, Claudia Lebedinsky, Guozhi Gao, Moshe Talpaz
Journal: Blood (2013)
Diagnostic Accuracy of a Defined Immunophenotypic and Molecular Genetic Approach for Peripheral T/NK-Cell Lymphomas: A North American PTCL Study Group Project
Authors: Eric D. Hsi, Jonathan Said, William R Macon, Scott J. Rodig, Randy D. Gascoyne, Sarah Ondrejka, David Dorfman, Elizabeth A. Morgan, Matthew J Maurer, Ahmet Dogan
Journal: Blood (2012)
High-Dose Cyclophosphamide + G-CSF Mobilization Regimen Have Higher Anti-Myeloma Effects Than G-CSF Alone Regimen – Single Institutional Study in 147 Myeloma Patients From Japan
Authors: Akira Tanimura, Masataka Takeshita, Atsushi Sato, Junichiro Takano, Hideaki Kitahara, Ayato Tsukamoto, Yuko Kimura, Risen Hirai, Miki Nakamura, Shotaro Hagiwara, Mineo Kurokawa, Akiyoshi Miwa
Journal: Blood (2011)
Normal Karyotype Primary Myelofibrosis (NK-PMF): Clinical and Molecular Prognostication In 690 Patients
Authors: Ayalew Tefferi, Paola Guglielmelli, Terra L Lasho, Christy Finke, Emnet A Wassie, Ryan A Knudson, Rhett P Ketterling, Curtis A. Hanson, Animesh Pardanani, Alessandro M Vannucchi
Journal: Blood (2013)
Successful Mobilization of Peripheral Blood Stem Cells After Intensive Bendamustine Pre-Treatment In Patients with Multiple Myeloma
Authors: Wolfram Pönisch, Julia Wiesler, Sabine Leiblein, Elvira Edel, Haifa K. Al-Ali, Nadezda Basara, Ute Hegenbart, Christiane Heiß, Dietger W Niederwieser, Hartmut Goldschmidt
Journal: Blood (2010)
Effects of Dose Modifications on Safety and Efficacy of Dacomitinib for EGFR+ NSCLC in ARCHER 1050 Japanese Subset
Authors: Terufumi Kato, Makoto Nishio, Seiji Niho, Noboru Yamamoto, Toshiaki Takahashi, Naoyuki Nogami, Hiroyasu Kaneda, Yuka Fujita, Keith Wilner, Mizuki Yoshida, Mitsuhiro Isozaki, Shinsuke Wada, Fumito Tsuji, Kazuhiko Nakagawa
Journal: Annals of Oncology (2019)
Structural Variations Involving Programmed Death Ligands in B-Cell and T-Cell Lymphomas
Authors: Keisuke Kataoka, Hiroaki Miyoshi, Yasunori Kogure, Yasuharu Sato, Kenji Nishida, Yuichi Shiraishi, Hiroko Tanaka, Kenichi Chiba, Yosaku Watatani, Yusuke Shiozawa, Kenichi Yoshida, Masashi Sanada, Motohiro Kato, Satoru Miyano, Koji Izutsu, Kengo Takeuchi, Tadashi Yoshino, Koichi Ohshima, Seishi Ogawa
Journal: Blood (2016)
Donor Lymphocyte Infusion (DLI) for Mixed Chimerism 6 Months after T Cell Depleted Allogeneic Stem Cell Transplantation (TCD alloSCT) May Prevent Relapse.
Authors: Erik W.A. Marijt, Peter A. Von Dem Borne, Renee M.Y. Barge, Piette P. Deutz, M. Floor Beaumont, C.W.J. Ingrid Starrenburg, Willem E. Fibbe, Roelof Willemze, J.H. Frederik Falkenburg
Journal: Blood (2006)
Significantly Inferior Overall and Event Free Survival in Pediatric Oncology Patients with Symptomatic Venous Thrombotic Events As Compared to Those without Symptomatic Venous Thrombotic Events: A Population Based Study from Maritimes, Canada
Authors: Zara Forbrigger, Carol Digout, Conrad Fernandez, Mark Bernstein, Ketan Kulkarni
Journal: Blood (2016)
Decreased Activity of NK Cells in Myeloproliferative Neoplasms
Authors: Adriana Queiroz Arantes, Cristina Tavares Leal, Cleide Araújo Silva, Priscila Santos Scheucher, Aglair Bergamo, Robert S. Welner, Daniel G. Tenen, Ann Mullally, Susumu Kobayashi, Eduardo Magalhaes Rego, Lorena Lobo Figueiredo-Pontes
Journal: Blood (2015)
Minimal Residual Disease Quantification in Acute Lymphoblastic Leukemia Using High-Throughput Sequencing of Multiple Immunoreceptor Genes Predicts Relapse and Survival After Allogeneic Hematopoietic Cell Transplantation.
Authors: Aaron C. Logan, Nikita Vashi, Malek Faham, Victoria Carlton, Ismael Buno, Jianbiao Zheng, Martin Moorhead, Mark Klinger, Tom Willis, Bing Zhang, Amna Waqar, James L. Zehnder, David B Miklos
Journal: Blood (2012)
Unresponsiveness to CHOP Is Associated with Activation of the p38 MAPK Pathway in Patients with DLBCL
Authors: Mario I Vega, Alejandro Aviles-Salas, J Ramon Chalapud, Sara Huerta-Yepez, Rogelio Hernandez-Pando, Melisa Martinez-Paniagua, Bernardo Martinez-Miguel, Miriam Hernandez-Atenogenes, Gabriel G Vega, Haiming Chen, James R. Berenson, Hector Mayani, Otoniel Martinez-Maza, Benjamin Bonavida
Journal: Blood (2011)
Detection of microRNAs in CD34+ Microparticles of Cord Blood Units
Authors: Angeliki Xagorari, Marina Geroussi, Anastasia Marvaki, Maria Samalidou, Antonia Sioga, Dimitris Bougiouklis, Anagnostis Argiriou, Achilles Anagnostopoulos, Damianos Sotiropoulos
Journal: Blood (2016)
Bortezomib (VELCADE®) Plus Dexamethasone as Induction Treatment Prior to Autologous Stem Cell Transplantation in Patients with Newly Diagnosed Multiple Myeloma: Preliminary Results of an IFM Phase II Study.
Authors: Jean-Luc Harousseau, Michel Attal, Xavier Leleu, Remy Gressin, Cyrille Hulin, Jean-Gabriel Fuzibet, Jacques Troncy
Journal: Blood (2004)
Response to Immunizations Following Allogeneic HCT with Adjuvant Rituximab Therapy.
Authors: Mary Pao, Esperanza B. Papadopoulos, Farid Boulad, Hugo Castro-Malaspina, Ann Jakubowski, Nancy A. Kernan, Miguel Perales, Susan Prockop, Ruth Ford, James W. Young, Richard J. O’Reilly, Trudy N. Small
Journal: Blood (2005)
High Frequencies Of Switching To 2nd TKIs and Failure To Maintain Standard Imatinib Dose In Japanese CML Patients With BIM Genetic Variants
Authors: Seiichiro Katagiri, Tetsuzo Tauchi, Tomohiro Umezu, Kazuhiro Ohtsuki, Kenichi Tadokoro, Yoshinori Yamamoto, Junko H Ohyashiki, Kazuma Ohyashiki
Journal: Blood (2013)
The Zebrafish Homologue of the Murine Ecotropic Viral Integration Site-1 (. Evi-1) gene Regulates Zebrafish Embryonic Blood Development.
Authors: Martina Konantz, Martijn H. Brugman, In-Hyun Park, George Q. Daley, Christiane Nuesslein-Volhard, Christopher Baum, Claudia Lengerke
Journal: Blood (2009)
Photopheresis in HIV-1 Infected Patients (pt) Using Benzoporphyrin Derivative (BPD-MA) Induces Apoptosis in CD4 Cells, Increases Intracellular Expression of Chemokines and Decreases HIV Infectivity and Viral Load.
Authors: Zale P. Bernstein, Thomas Dougherty, Stanley A. Schwartz, Sandra Gollnick, Carlton Stewart, Harold Walder, M. P. Nair, S. D. Mahajan, Adam Sumlin, Patricia Marhsall, Bernard Poiesz
Journal: Blood (2005)
Quizartinib in FLT3-ITD-Mutated Relapsed/Refractory Acute Myeloid Leukemia: QuANTUM-R Trial Results
Authors: Jorge E. Cortes, Samer Khaled, Giovanni Martinelli, Alexander E. Perl, Siddhartha Ganguly, Nigel H. Russell, Alwin Kramer, Herve Dombret, Donna Hogge, Brian A. Jonas, Anskar Yh Leung, Priyanka Mehta, Pau Montesinos, Markus P. Radsak, Simona Sica, Meena Arunachalam, Melissa Holmes, Ruth Namuyinga, Yufen Zhang, Mark J. Levis
Journal: Annals of Oncology (2019)
Preclinical Evidence That Trametinib Enhances the Response to Tyrosine Kinase Inhibitors in Acute Myeloid Leukemia
Authors: Joaquín Martínez-López, María Linares, Maria Luz Morales, Alicia Arenas, Ivana Zagorac, Rosa M. Ayala, Nerea Castro, Inmaculada Rapado, Miguel Quintela-Fandino
Journal: Blood (2016)
MD Anderson Scoring System (MDACC) Predicts Outcomes After Hematopoietic Stem Cell Transplantation (HSCT) Better Than Other Prognostic Classifications In MDS
Authors: Piyanuch Kongtim, Uday R Popat, Marcos de Lima, Guillermo Garcia-Manero, Elias J. Jabbour, Juliane Chen, Gabriela Rondon, Lynne V. Abruzzo, Stefan O. Ciurea, Elizabeth J Shpall, Richard E Champlin, Betul Oran
Journal: Blood (2013)
The Integrin Co-Activator Kindlin-2 Plays a Critical Role In Angiogenesis and Blood Vessel Integrity
Authors: Elzbieta Pluskota, James J Dowling, Natalie Gordon, Jeffrey A Golden, Dorota Szpak, XiaoXia Zhang, Carla Nestor, Yan-Qing Ma, Katarzyna Bialkowska, Tatiana Byzova, Edward F. Plow
Journal: Blood (2010)
Janus Kinases Interact with and Phosphorylate Rack-1 (Receptor for Activated C Kinase-1), a WD Motif Containing Protein.
Authors: Takashi Haro, Kazuya Shimoda, Haruko Kakumitsu, Kenjirou Kamezaki, Atsuhiko Numata, Mine Harada
Journal: Blood (2004)
A Phase II Study of the Farnesyltransferase Inhibitor Tipifarnib Demonstrates Anti-Tumor Activity In Patients with Relapsed and Refractory Lymphomas
Authors: Thomas E. Witzig, Tang Hui, Ivana N Micallef, Stephen M. Ansell, Brian Link, David James Inwards, Luis Porrata, Patrick B Johnston, Joseph Colgan, Svetomir Markovic, Grzegorz S. Nowakowski, Carrie A Thompson, Cristine Allmer, Matthew J Maurer, George Weiner, Raymond J. Hohl, Paul Kurtin, Husheng Ding, Loegering A David, Paula A Schneider, Kevin L Peterson, Thomas M. Habermann, Scott H. Kaufmann
Journal: Blood (2010)
In Vitro Growth Inhibition, Target Modulation and Drug Synergy In Pediatric Leukemia By The Novel Proteasome Inhibitor Carfilzomib
Authors: Aarthi Jayanthan, Yibing Ruan, Meaghan Hagerty, Ravi Shah, Tony Truong, Victor A. Lewis, Jessica Boklan, Tanya Trippett, Lia Gore, Aru Narendran
Journal: Blood (2013)
DNMT3A Mutations in AML Patients: Prognostic Impact and Comparative Analysis of Mutations Burden in Diagnostic Samples, after Standard Therapy, and after Allogeneic Stem Cell Transplantation
Authors: Olga Blau, Franziska Behrenbeck, Nikola Suckert, Lars R. Fransecky, Claudia D. Baldus, Renate Arnold, Antonio Pezzutto, Bernd Dörken, Igor Wolfgang Blau
Journal: Blood (2016)
Preliminary Results from the North American Acute Promyelocytic Leukemia (APL) Study C9710.
Authors: Bayard L. Powell, Barry Moser, Wendy Stock, Robert E. Gallagher, Cheryl L. Willman, Richard M. Stone, Jacob M. Rowe, Steven Coutre, James H. Feusner, John Gregory, Stephen Couban, Frederick R. Appelbaum, Martin S. Tallman, Richard A. Larson
Journal: Blood (2006)
The potential and controversy of targeting STAT family members in cancer
Authors: Yannick Verhoeven, Sam Tilborghs, Julie Jacobs, Jorrit De Waele, Delphine Quatannens, Christophe Deben, Hans Prenen, Patrick Pauwels, Xuan Bich Trinh, An Wouters, Evelien L.J. Smits, Filip Lardon, Peter A. van Dam
Journal: Seminars in Cancer Biology (2019)

The Signal Transducer and Activator of Transcription (STAT) family of proteins consists of transcription factors that play a complex and essential role in the regulation of physiologic cell processes, such as proliferation, differentiation, apoptosis and angiogenesis, and serves to organize the epigenetic landscape of immune cells. To date, seven STAT genes have been identified in the human genome; STAT1, STAT2, STAT3, STAT4, STAT5a, STAT5b and STAT6. They all account for diverse effects in response to extracellular signaling proteins, mainly by altering gene transcription in the effector cells. Members of the STAT family have been implicated in human cancer development, progression, metastasis, survival and resistance to treatment. Particularly STAT3 and STAT5 are of interest in cancer biology. They are currently considered as oncogenes, but their signaling is embedded into a complex and delicate balance between different (counteracting) transcription factors, and thus, in some contexts they can have a tumor suppressive role. Assessing STAT signaling mutations as well as screening for aberrant STAT pathway activation may have a role to predict sensitivity to immunotherapy and targeted STAT inhibition. In the present comprehensive review of the literature, we discuss in-depth the role of each STAT family member in cancer, assemble cutting-edge information on the use of these molecules as potential biomarkers and targets for treatment, and address why their clinical implementation is controversy.
Introduction of the Kit Mutation into Immunodeficient Mice Enables Xenogeneic Reconstitution of Human Megakaryocyte-Erythroid Hematopoietic System
Authors: Yurino Ayano, Takuji Yamauchi, Takuya Nunomura, Yasufumi Uehara, Fumiaki Jinnouchi, Shinya Daitoku, Yuya Kunisaki, Katsuto Takenaka, Koichi Akashi
Journal: Blood (2015)
Personal antigen selection calculator (PASCal) for the design of personal cancer vaccines
Authors: E. Somogyi, Z. Csiszovszki, O. Lorincz, J. Toth, L. Molnar, W. Schönharting, S. Urban, T. Röhnisch, K. Pántya, P. Pales, M. Megyesi, E.R. Tőke
Journal: Annals of Oncology (2019)
Gene Expression Profiling in Adult Acute Lymphoblastic Leukemia, Biphenotypic Acute Leukemia, and Acute Myeloid Leukemia M0: Confirmation of Immunophenotypic and Cytogenetic Diagnostic Findings.
Authors: Wolfgang Kern, Alexander Kohlmann, Claudia Schoch, Martin Dugas, Sylvia Merk, Wolfgang Hiddemann, Susanne Schnittger, Torsten Haferlach
Journal: Blood (2004)
Human signal transducer and activator of transcription 5b (STAT5b) mutation causes dysregulated human natural killer cell maturation and impaired lytic function
Authors: Alexander Vargas-Hernández, Agnieszka Witalisz-Siepracka, Michaela Prchal-Murphy, Klara Klein, Sanjana Mahapatra, Waleed Al-Herz, Emily M. Mace, Alexandre F. Carisey, Jordan S. Orange, Veronika Sexl, Lisa R. Forbes
Journal: Journal of Allergy and Clinical Immunology (2019)

Patients with signal transducer and activator of transcription 5b (STAT5b) deficiency have impairment in T-cell homeostasis and natural killer (NK) cells which leads to autoimmunity, recurrent infections, and combined immune deficiency.In this study we characterized the NK cell defect in STAT5b-deficient human NK cells, as well as Stat5b-/- mice.We used multiparametric flow cytometry, functional NK cell assays, microscopy, and a Stat5b-/- mouse model to elucidate the effect of impaired and/or absent STAT5b on NK cell development and function.This alteration generated a nonfunctional CD56bright NK cell subset characterized by low cytokine production. The CD56dim NK cell subset had decreased expression of perforin and CD16 and a greater frequency of cells expressing markers of immature NK cells. We observed low NK cell numbers and impaired NK cell maturation, suggesting that STAT5b is involved in terminal NK cell maturation in Stat5b-/- mice. Furthermore, human STAT5b-deficient NK cells had low cytolytic capacity, and fixed-cell microscopy showed poor convergence of lytic granules. This was accompanied by decreased expression of costimulatory and activating receptors. Interestingly, granule convergence and cytolytic function were restored after IL-2 stimulation.Our results show that in addition to the impaired terminal maturation of NK cells, human STAT5b mutation leads to impairments in early activation events in NK cell lytic synapse formation. Our data provide further insight into NK cell defects caused by STAT5b deficiency.
Extending Autologous Hematopoietic Stem Cell Transplantation As First Line Treatment in Multiple Myeloma Patients with Severe Renal Impairment: A Retrospective Study of the Francophone Society of Stem Cell Transplantation and Cellular Therapy (SFGM-TC)
Authors: Karine Augeul-Meunier, Denis Caillot, Anne-Marie Stoppa, Lionel Karlin, Lofti Benboubker, Natacha Maillard, Mohamad Mohty, Ibrahim Yakoub-Agha, Jacques-Olivier Bay, Caroline Bonmati, Claude-Eric Bulabois, Anne Huynh, Melanie Mercier, Laurent Frenzel, Herve Avet-Loiseau, Jerome Cornillon
Journal: Blood (2016)
Endogenous N-Terminal Truncated STAT5 Expressed from Alternative Start Codons Promotes SCF Signaling in Murine Primary Mast Cell Cultures.
Authors: Kevin D. Bunting, Christine Couldrey, Richard Moriggl, Yongzhi Cui, Harry Wright, Demin Wang, John J. Ryan, James N. Ihle, Lothar Hennighausen
Journal: Blood (2004)
Improved Prognosis for Older Adolescents with Acute Lymphoblastic Leukemia
Authors: Sima Jeha, Deqing Pei, Dario Campana, W. Paul Bowman, John Sandlund, Sue Kaste, Raul C. Ribeiro, Jeffrey E. Rubnitz, Elaine Coustan-Smith, Cheng Cheng, Monika L. Metzger, Deepa Bhojwani, Hiroto Inaba, Susana C. Raimondi, Mihaela Onciu, Scott C. Howard, Wing H. Leung, James R. Downing, William E. Evans, Mary . Relling, Ching-Hon Pui
Journal: Blood (2010)
Germline <i>GPR161</i> Mutations Predispose to Pediatric Medulloblastoma
Authors: Matthias Begemann, Sebastian M. Waszak, Giles W. Robinson, Natalie Jäger, Tanvi Sharma, Cordula Knopp, Florian Kraft, Olga Moser, Martin Mynarek, Lea Guerrini-Rousseau, Laurence Brugieres, Pascale Varlet, Torsten Pietsch, Daniel C. Bowers, Murali Chintagumpala, Felix Sahm, Jan O. Korbel, Stefan Rutkowski, Thomas Eggermann, Amar Gajjar, Paul Northcott, Miriam Elbracht, Stefan M. Pfister, Udo Kontny, Ingo Kurth
Journal: Journal of Clinical Oncology (2019)

PURPOSE The identification of a heritable tumor predisposition often leads to changes in management and increased surveillance of individuals who are at risk; however, for many rare entities, our knowledge of heritable predisposition is incomplete. METHODS Families with childhood medulloblastoma, one of the most prevalent childhood malignant brain tumors, were investigated to identify predisposing germline mutations. Initial findings were extended to genomes and epigenomes of 1,044 medulloblastoma cases from international multicenter cohorts, including retrospective and prospective clinical studies and patient series. RESULTS We identified heterozygous germline mutations in the G protein-coupled receptor 161 ( GPR161) gene in six patients with infant-onset medulloblastoma (median age, 1.5 years). GPR161 mutations were exclusively associated with the sonic hedgehog medulloblastoma (MB SHH ) subgroup and accounted for 5% of infant MB SHH cases in our cohorts. Molecular tumor profiling revealed a loss of heterozygosity at GPR161 in all affected MB SHH tumors, atypical somatic copy number landscapes, and no additional somatic driver events. Analysis of 226 MB SHH tumors revealed somatic copy-neutral loss of heterozygosity of chromosome 1q as the hallmark characteristic of GPR161 deficiency and the primary mechanism for biallelic inactivation of GPR161 in affected MB SHH tumors. CONCLUSION Here, we describe a novel brain tumor predisposition syndrome that is caused by germline GPR161 mutations and characterized by MB SHH in infants. Additional studies are needed to identify a potential broader tumor spectrum associated with germline GPR161 mutations.
High-Dose (HD) Imatinib Provides Better Responses in Patients with Untreated Early Chronic Phase (CP) CML.
Authors: tsuko Aoki, Hagop Kantarjian, Susan O’Brien, Moshe Talpaz, Francis Giles, Srdan Verstovsek, William Wierda, August Salavado, Lauri Letvak, Guillermo Garcia-Manero, Dan Jones, Rajyalakshmi Luthra, Jianqin Shan, Jorge Cortes
Journal: Blood (2006)
The Triple Combination of the CD20 Antibody Obinutuzumab with the Bcl-2 Inhibitor Venetoclax (GDC-199) and the MDM2 Inhibitor Idasanutlin Results in Superior Efficacy and Long Term Response in Wildtype p53 NHL Tumor Models
Authors: Frank Herting, Thomas Friess, Pablo Umaña, Middleton Steven, Christian Klein
Journal: Blood (2016)